123 related articles for article (PubMed ID: 32627369)
1. Effect of Glucose on Liposome-Plasma Protein Interactions: Relevance for the Physiological Response of Clinically Approved Liposomal Formulations.
Palchetti S; Digiacomo L; Pozzi D; Zenezini Chiozzi R; Capriotti AL; Laganà A; Coppola R; Caputo D; Sharifzadeh M; Mahmoudi M; Caracciolo G
Adv Biosyst; 2019 Feb; 3(2):e1800221. PubMed ID: 32627369
[TBL] [Abstract][Full Text] [Related]
2. Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery.
Caracciolo G; Palchetti S; Digiacomo L; Chiozzi RZZ; Capriotti AL; Amenitsch H; Tentori PM; Palmieri V; Papi M; Cardarelli F; Pozzi D; Laganà A
ACS Appl Mater Interfaces; 2018 Jul; 10(27):22951-22962. PubMed ID: 29905462
[TBL] [Abstract][Full Text] [Related]
3. Clinically approved PEGylated nanoparticles are covered by a protein corona that boosts the uptake by cancer cells.
Papi M; Caputo D; Palmieri V; Coppola R; Palchetti S; Bugli F; Martini C; Digiacomo L; Pozzi D; Caracciolo G
Nanoscale; 2017 Jul; 9(29):10327-10334. PubMed ID: 28702661
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles.
Hadjidemetriou M; Al-Ahmady Z; Mazza M; Collins RF; Dawson K; Kostarelos K
ACS Nano; 2015 Aug; 9(8):8142-56. PubMed ID: 26135229
[TBL] [Abstract][Full Text] [Related]
5. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona.
Caracciolo G
Nanoscale; 2018 Mar; 10(9):4167-4172. PubMed ID: 29450412
[TBL] [Abstract][Full Text] [Related]
6. Effects of the protein corona on liposome-liposome and liposome-cell interactions.
Corbo C; Molinaro R; Taraballi F; Toledano Furman NE; Sherman MB; Parodi A; Salvatore F; Tasciotti E
Int J Nanomedicine; 2016; 11():3049-63. PubMed ID: 27445473
[TBL] [Abstract][Full Text] [Related]
7. Tuning liposome composition to modulate corona formation in human serum and cellular uptake.
Yang K; Mesquita B; Horvatovich P; Salvati A
Acta Biomater; 2020 Apr; 106():314-327. PubMed ID: 32081780
[TBL] [Abstract][Full Text] [Related]
8. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
[TBL] [Abstract][Full Text] [Related]
9. Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer.
Palchetti S; Caputo D; Digiacomo L; Capriotti AL; Coppola R; Pozzi D; Caracciolo G
Pharmaceutics; 2019 Jan; 11(1):. PubMed ID: 30650541
[TBL] [Abstract][Full Text] [Related]
10. Impact of the biomolecular corona on the structure of PEGylated liposomes.
Digiacomo L; Pozzi D; Amenitsch H; Caracciolo G
Biomater Sci; 2017 Aug; 5(9):1884-1888. PubMed ID: 28676869
[TBL] [Abstract][Full Text] [Related]
11. Exploring Cellular Interactions of Liposomes Using Protein Corona Fingerprints and Physicochemical Properties.
Bigdeli A; Palchetti S; Pozzi D; Hormozi-Nezhad MR; Baldelli Bombelli F; Caracciolo G; Mahmoudi M
ACS Nano; 2016 Mar; 10(3):3723-37. PubMed ID: 26882007
[TBL] [Abstract][Full Text] [Related]
12. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
13. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
14. The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study.
Hadjidemetriou M; McAdam S; Garner G; Thackeray C; Knight D; Smith D; Al-Ahmady Z; Mazza M; Rogan J; Clamp A; Kostarelos K
Adv Mater; 2019 Jan; 31(4):e1803335. PubMed ID: 30488990
[TBL] [Abstract][Full Text] [Related]
15. Personalized liposome-protein corona in the blood of breast, gastric and pancreatic cancer patients.
Colapicchioni V; Tilio M; Digiacomo L; Gambini V; Palchetti S; Marchini C; Pozzi D; Occhipinti S; Amici A; Caracciolo G
Int J Biochem Cell Biol; 2016 Jun; 75():180-7. PubMed ID: 26369869
[TBL] [Abstract][Full Text] [Related]
16. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells.
Pozzi D; Colapicchioni V; Caracciolo G; Piovesana S; Capriotti AL; Palchetti S; De Grossi S; Riccioli A; Amenitsch H; Laganà A
Nanoscale; 2014 Mar; 6(5):2782-92. PubMed ID: 24463404
[TBL] [Abstract][Full Text] [Related]
17. Amphiphilic dendrimers control protein binding and corona formation on liposome nanocarriers.
Wagner J; Dillenburger M; Simon J; Oberländer J; Landfester K; Mailänder V; Ng DYW; Müllen K; Weil T
Chem Commun (Camb); 2020 Aug; 56(61):8663-8666. PubMed ID: 32608398
[TBL] [Abstract][Full Text] [Related]
18. Functionalization of Liposomes with Hydrophilic Polymers Results in Macrophage Uptake Independent of the Protein Corona.
Weber C; Voigt M; Simon J; Danner AK; Frey H; Mailänder V; Helm M; Morsbach S; Landfester K
Biomacromolecules; 2019 Aug; 20(8):2989-2999. PubMed ID: 31268685
[TBL] [Abstract][Full Text] [Related]
19. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles.
Hadjidemetriou M; Al-Ahmady Z; Kostarelos K
Nanoscale; 2016 Apr; 8(13):6948-57. PubMed ID: 26961355
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence Lifetime Nanoscopy of Liposomal Irinotecan Onivyde: From Manufacturing to Intracellular Processing.
Bernardi M; Signore G; Moscardini A; Pugliese LA; Pesce L; Beltram F; Cardarelli F
ACS Appl Bio Mater; 2023 Oct; 6(10):4277-4289. PubMed ID: 37699572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
